Study S000118

The Effect of Cagrilintide and Semaglutide Combination Treatment Compared to a Weight-loss Inducing Diet on Energy Metabolism in Persons Living With Obesity: an Open-label Randomised Study

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07184086
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 80
Start: 2025-09-26
Primary completion: 2027-10-12
Lead sponsor: Novo Nordisk A/S
Conditions: Obesity
Interventions: DRUG:CagriSema (Cagrilintide B + semaglutide I); BEHAVIORAL:Low Energy Diet
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1316-8299

Registered primary outcomes

Change in sleeping metabolic rate (SMR) [Baseline (Week 0) to Week 20]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.